Advertisement
Advertisement
PROF
Profound Medical Corp. Common Stock
6.85
USDSponsored
-0.31
-4.33%
May 08, 16:00 UTC -4
Closed
After-Market
6.89
+0.04
+0.58%
PROF Earnings Reports
Positive Surprise Ratio
PROF beat 16 of 41 last estimates.
39%
Next Report
Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
$6.26M
/-$0.25
Implied change from Q1 26 (Revenue/ EPS)
+17.27%
/+31.58%
Implied change from Q2 25 (Revenue/ EPS)
+183.22%
/-51.92%
Profound Medical Corp. Common Stock earnings per share and revenue
On May 07, 2026, PROF reported earnings of -0.19 USD per share (EPS) for Q1 26, beating the estimate of -0.25 USD, resulting in a 25.75% surprise. Revenue reached 5.34 million, compared to an expected 5.02 million, with a 6.45% difference. The market reacted with a -4.33% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of -0.25 USD, with revenue projected to reach 6.26 million USD, implying an increase of 31.58% EPS, and increase of 17.27% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.37
Surprise
-9.82%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
4D Molecular Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.01
Actual
-$1.01
Surprise
+0.21%
Akebia Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-4.90%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.37
Surprise
-17.01%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
Nektar Therapeutics
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.62
Actual
-$1.82
Surprise
-11.88%
Definium Therapeutics, Inc. Common Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.71
Surprise
-41.43%
FAQ
What were Profound Medical Corp. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Profound Medical Corp. Common Stock reported EPS of -$0.19, beating estimates by 25.75%, and revenue of $5.34M, 6.45% above expectations.
How did the market react to Profound Medical Corp. Common Stock's Q1 2026 earnings?
The stock price moved down -4.33%, changed from $7.16 before the earnings release to $6.85 the day after.
When is Profound Medical Corp. Common Stock expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for Profound Medical Corp. Common Stock's next earnings report?
Based on 4
analysts, Profound Medical Corp. Common Stock is expected to report EPS of -$0.25 and revenue of $6.26M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement